{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:57Z","timestamp":1787070897452,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We describe the 18F-fluorodeoxyglucose positron emission tomography\/contrast enhanced computed tomography (FDG PET\/CECT) images of a 63-year-old male who complained of back pain and was suspected of multiple myeloma based on magnetic resonance imaging. PET\/CECT suggested the FDG avid lesion involving prostate, accompanied by multiple lytic skeletal lesions with no evidence to suggest other possible primary site. A bone marrow biopsy suggested a metastatic adenocarcinoma of primary prostatic origin. Post anti-androgen therapy follow-up FDG PET\/CT revealed reductions in the metabolic activities and soft tissue components of most of the metastatic skeletal lesions. These images highlight the possible indication of FDG PET\/CT in evaluation of prostatic malignancy in era of 68Ga-PSMA.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1073_22","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T06:39:55Z","timestamp":1664865595000},"page":"S939-S942","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The lytic skeletal lesions: A rare presentation of carcinoma prostate on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography"],"prefix":"10.4103","volume":"19","author":[{"given":"Shantanu","family":"Pande","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, All India Institutes of Medical Sciences, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihit","family":"Mhatre","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tata Memorial Hospital, Dr. E Borges Marg, Parel East, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Dhal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Homi Bhabha Cancer Hospital and Mahamana Pandit Madanmohan Malaviya Cancer Centre, Sundar Bagiya, BHU Campus, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcp.20166","article-title":"Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer","volume":"202","author":"Macheda","year":"2005","journal-title":"J Cell Physiol"},{"key":"R2-20241021","first-page":"369","article-title":"Dominant uptake of fatty acid over glucose by prostate cells: A potential new diagnostic and therapeutic approach","volume":"30","author":"Liu","year":"2010","journal-title":"Anticancer Res"},{"key":"R3-20241021","first-page":"349","article-title":"68Ga-PSMA-11 in prostate cancer: A comprehensive review","volume":"10","author":"Bois","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R4-20241021","first-page":"120","article-title":"A review on the clinical utility of PSA in cancer prostate","volume":"3","author":"Adhyam","year":"2012","journal-title":"Indian J SurgOncol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s12149-008-0177-5","article-title":"[F-18]-Fluorodeoxyglucose PET-CT of the normal prostate gland","volume":"22","author":"Jadvar","year":"2008","journal-title":"Ann Nucl Med"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-013-2361-7","article-title":"Imaging evaluation of prostate cancer with 18Ffluorodeoxyglucose PET\/CT: Utility and limitations","volume":"40","author":"Jadvar","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","article-title":"Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer","volume":"57","author":"Liu","year":"2001","journal-title":"Urology"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-05-0249","article-title":"2-[18F] Fluoro- 2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy","volume":"11","author":"Sch\u00f6der","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18FFDG, 18F- or 11Cacetate, and 18F- or 11Ccholine","volume":"52","author":"Jadvar","year":"2011","journal-title":"J Nucl Med"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<257::AID-IJC15>3.0.CO;2-3","article-title":"Overproduction of parathyroid hormonerelated peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo","volume":"80","author":"Rabbani","year":"1999","journal-title":"Int J Cancer"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1148\/radiology.199.3.8638000","article-title":"Metastatic prostate cancer: Initial findings of PET with 2deoxy2- F18 fluoroDglucose","volume":"199","author":"Shreve","year":"1996","journal-title":"Radiology"},{"key":"R12-20241021","first-page":"946","article-title":"Comparison of bone scintigraphy and 18FFDG PETCT in a prostate cancer patient with osteolytic bone metastases","volume":"30","author":"Kara","year":"2011","journal-title":"Rev Esp Med Nucl"},{"key":"R13-20241021","first-page":"4259","article-title":"Investigations with FDGPET scanning in prostate cancer show limited value for clinical practice","volume":"41","author":"Salminen","year":"2002","journal-title":"ActaOncol"},{"key":"R14-20241021","first-page":"5026","article-title":"Is there use for FDGPET in prostate cancer?","volume":"46","author":"Jadvar","year":"2016","journal-title":"SeminNucl Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1073_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:30Z","timestamp":1787067510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1073_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":14,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1073_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"2022-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}